Navigation Links
New research suggests common anti-seizure medications may increase risk of cardiovascular problems
Date:3/18/2009

PHILADELPHIA An important clinical repercussion in the treatment of epilepsy has been discovered by a research team led by Scott Mintzer, M.D., assistant professor in the Department of Neurology and the Jefferson Comprehensive Epilepsy Center at Jefferson Medical College of Thomas Jefferson University. The team has determined that two of the most commonly prescribed anti-seizure medications may lead to significantly increased levels of cholesterol, C-reactive protein and other markers of cardiovascular disease risk. The finding set to be published in the March 18th online edition of Annals of Neurology may help doctors manage the care of patients with seizures more effectively by prescribing different anti-seizure medications that will not adversely affect cardiovascular health.

The study involved two of the most widely-prescribed anticonvulsants phenytoin (Dilantin) and carbamazepine (Tegretol, Carbatrol) which have potent effects on many enzymes in the body involved in different areas of metabolism. The researchers recruited 34 epilepsy patients taking either one of those two drugs who were being switched over to one of two newer anti-seizure drugs which do not widely affect enzymes lamotrigine (Lamictal) or levetiracetam (Keppra). The goal was to determine if the change affected the patients' cholesterol levels and other key markers of cardiovascular disease.

Just 6 weeks after the patients' drugs were switched, there were significant declines in total cholesterol, non-high-density lipoprotein (commonly referred to as 'bad') cholesterol, triglycerides and C-reactive protein, suggesting the older, commonly-used drugs might substantially increase the risk of cardiovascular disease.

"The epilepsy patients in this study saw a rapid and clinically significant improvement in several markers related to cardiovascular disease, including a decrease in total cholesterol that averaged 26 points. This is almost certainly not due to some positive effect from the new drugs. It's a consequence of being taken off the older ones, which were causing the cholesterol and other markers to be elevated in the first place," said Dr. Mintzer. "While more investigation is needed, these results may help physicians better understand the risks of these drugs and choose the most appropriate treatment for their epilepsy patients, especially those who are already at risk for cardiovascular disease or have a family history of it."

According to the Epilepsy Foundation, which also funded this study, there are almost three million people living with epilepsy with an additional 200,000 new diagnoses being made each year. Dilantin is the most commonly prescribed anticonvulsant in this country, and has been since its discovery in 1938. Throughout the industrialized world, Tegretol has been the most commonly prescribed anticonvulsant for more than 20 years. The results of this study could have far-reaching effects on how the millions of current, and future patients are, or will be, treated.


'/>"/>

Contact: Ed Federico
ed.federico@jefferson.edu
215-955-5507
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Researcher wins $2.6 million grant for depression care study
2. Frost and Sullivan Picks Epinex for Diabetes Research Award
3. Foundation for Biomedical Research Releases Groundbreaking PSA
4. Fish health claims may cause more environmental harm than good: UBC-St. Michaels researchers
5. IADR Oral Medicine and Pathology Research Award presented to UCLA professor
6. Researchers clone key sperm-binding proteins
7. Collagen injections can help some incontinence patients when surgery fails, researcher finds
8. Research Finds Popular Household Pets Transmit Dangerous Parasites to Humans
9. Researchers find sustained improvement in health in Experience Corps tutors over 55
10. Researchers develop DNA patch for canine form of muscular dystrophy
11. University of Notre Dame Chooses Latest Technology From Carestream Molecular Imaging For Disease Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Rochester, NY (PRWEB) , ... January 19, 2017 ... ... release of Clinical Conductor CTMS, which provides a modern CTMS workflow designed to ... patient management information has been condensed to a single page, maximizing usability and ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... and staff members in 2017 who are passionate about making a difference in ... 1994 and headquartered in Tampa, UMA, a nonprofit healthcare educational institution, has more ...
(Date:1/19/2017)... NJ (PRWEB) , ... January 19, 2017 , ... ... locally owned insurance agency which serves Lawrenceville, New Jersey and the surrounding area, ... , Amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease ...
(Date:1/19/2017)... ... January 18, 2017 , ... The CHP suggests that California drivers can avoid ... slowing down and increasing the space between themselves and other vehicles, according to a ... attorney Raymond R. Hassanlou notes that, rain or shine, drivers should always incorporate safe ...
(Date:1/19/2017)... ... January 19, 2017 , ... "ProParagraph Basics is a set ... process for all media productions," said Christina Austin - CEO of Pixel Film ... self-animating paragraphs designed for multi-lined text purposes. Choose from presets with basic, ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 18, 2017 , , Marks E-QURE ... distribution agreement, following similar agreements in Israel ... care is $2 5 billion global ... Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of advanced ... Equipos Médicos S.A.S. (TeckMedica) in Colombia for the Company,s ...
(Date:1/19/2017)... Md. , Jan. 18, 2017   ... late-stage clinical company developing therapeutics designed to preserve ... of patients, today confirmed plans to initiate a ... Company,s modified-release reformulation of lovastatin lactone designed to ... smithii) in the gut to treat the ...
(Date:1/18/2017)... Jan. 18, 2017  EnteroMedics Inc. (NASDAQ: ... using neuroblocking technology to treat obesity, metabolic diseases ... of an underwritten public offering of units for ... underwriting discounts and commissions and offering expenses payable ... of Class A Units, priced at a public ...
Breaking Medicine Technology: